Micro Hydro Power

Micro Hydro Power by Frederick J. Munster Department of Economic and Community Development, August, Me. 1999 (?). Contents: Introduction / History of Hydropower in Maine / Renewables / Why Micro Hydro / Determining Flow / Determining Head / Estimating Energy Potential / Hydro Turbines / Dams, Impoundments, Penstocks and Power Houses / Utility Interconnected Systems / Battery Charging Systems / Operation and Maintenance / Economics / Regulation of Hydro Development / For More Information / Referenceshttps://digitalcommons.usm.maine.edu/me_collection/1123/thumbnail.jp

Self-consistent bounces in two dimensions

We compute bounce solutions describing false vacuum decay in a Phi**4 model in two dimensions in the Hartree approximation, thus going beyond the usual one-loop corrections to the decay rate. We use zero energy mode functions of the fluctuation operator for the numerical computation of the functional determinant and the Green's function. We thus avoid the necessity of discretizing the spectrum, as it is necessary when one uses numerical techniques based on eigenfunctions. Regularization is performed in analogy of standard perturbation theory; the renormalization of the Hartree approximation is based on the two-particle point-irreducible (2PPI) scheme. The iteration towards the self-consistent solution is found to converge for some range of the parameters. Within this range we find the corrections to the leading one-loop approximation to be relatively small, not exceeding one order of magnitude in the total transition rate.Comment: 30 pages, 12 figure

Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay.

BackgroundGlucocorticoid receptor (GR) activity plays a role in many aspects of human physiology and may play a crucial role in chemotherapy resistance in a wide variety of solid tumors. A novel immunohistochemistry (IHC) based assay has been previously developed and validated in order to assess GR immunoreactivity in triple-negative breast cancer. The current study investigates the standardized use of this validated assay to assess GR expression in a broad range of solid tumor malignancies.MethodsArchived formalin-fixed paraffin-embedded tumor bank samples (n=236) from 20 different solid tumor types were analyzed immunohistochemically. Nuclear staining was reported based on the H-score method using differential intensity scores (0, 1+, 2+, or 3+) with the percent stained (out of at least 100 carcinoma cells) recorded at each intensity.ResultsGR was expressed in all tumor types that had been evaluated. Renal cell carcinoma, sarcoma, cervical cancer, and melanoma were those with the highest mean H-scores, indicating high levels of GR expression. Colon, endometrial, and gastric cancers had lower GR staining percentages and intensities, resulting in the lowest mean H-scores.ConclusionA validated IHC assay revealed GR immunoreactivity in all solid tumor types studied and allowed for standardized comparison of reactivity among the different malignancies.ImpactBaseline expression levels of GR may be a useful biomarker when pharmaceutically targeting GR in research or clinical setting

Monte Carlo simulation of SU(2) Yang-Mills theory with light gluinos

In a numerical Monte Carlo simulation of SU(2) Yang-Mills theory with light dynamical gluinos the low energy features of the dynamics as confinement and bound state mass spectrum are investigated. The motivation is supersymmetry at vanishing gluino mass. The performance of the applied two-step multi-bosonic dynamical fermion algorithm is discussed.Comment: latex, 48 pages, 16 figures with epsfi

Tackling Ebola: new insights into prophylactic and therapeutic intervention strategies

Since its discovery in 1976, Ebolavirus has caused periodic outbreaks of viral hemorrhagic fever associated with severe and often fatal disease. Ebolavirus is endemic in Central Africa and the Philippines. Although there is currently no approved treatment available, the past 10 years has seen remarkable progress in our understanding of the pathogenicity of Ebolavirus and the development of prophylactic and post-exposure therapies against it. In vitro and in vivo experiments have shown that Ebolavirus pathogenicity is multifactorial, including viral and host determinants. Besides their function in the virus replication cycle, the viral glycoprotein, nucleoprotein, minor matrix protein and polymerase cofactor are viral determinants of pathogenicity, with evasion of the host innate and adaptive immune responses as the main mechanism. Although no licensed Ebolavirus vaccines are currently available, vaccine research in non-human primates, the 'gold standard' animal model for Ebolavirus, has produced several promising candidates. A combination of DNA vaccination and a recombinant adenovirus serotype 5 boost resulted in cross-protective immunity in non-human primates. A recombinant vesicular stomatitis vaccine vector protected non-human primates in pre- and post-exposure challenge studies. Several antiviral therapies are currently under investigation, but only a few of these have been tested in non-human primate models. Antisense therapies, in which oligonucleotides inhibit viral replication, have shown promising results in non-human primates following post-exposure treatment. In light of the severity of Ebolavirus disease and the observed increase in Ebolavirus outbreaks over the past decade, the expedited translation of potential candidate therapeutics and vaccines from bench to bedside is currently the most challenging task for the field. Here, we review the current state of Ebolavirus research, with emphasis on prophylactic and therapeutic intervention strategies

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.

BackgroundSrc inhibitors sensitise melanoma cells to chemotherapy in preclinical models. The combination of dasatinib and dacarbazine was tested in a phase I trial in melanoma.MethodsPatients had ECOG performance status 0-2 and normal organ function. Dacarbazine was administered on day 1 and dasatinib on day 2 through 19 of each 21-day cycle. Both were escalated from 50 mg b.i.d. of dasatinib and 800 mg m(-2) of dacarbazine. Available pre-treatment biopsies were sequenced for BRAF, NRAS, and C-Kit mutations.ResultsDose-limiting toxicity was reached at dasatinib 70 mg b.i.d./dacarbazine 1000 mg m(-2), and was predominantly haematological. In 29 patients receiving dasatinib 70 mg b.i.d., the objective response rate (ORR) was 13.8%, the clinical benefit rate (ORR+SD) was 72.4%, the 6-month progression-free survival (PFS) was 20.7%, and the 12-month overall survival (OS) was 34.5%. Two out of three patients who were wild type for BRAF, NRAS, and c-KIT mutations had confirmed partial responses, and one had a minor response.ConclusionThe recommended phase II dose is dasatinib 70 mg b.i.d with dacarbazine 800 mg m(-2). PFS and OS data for dasatinib at 70 mg b.i.d. with dacarbazine compared favourably with historical controls. Preliminary data support evaluating tumour mutation status further as a biomarker of response

One-loop corrections to the metastable vacuum decay

We evaluate the one-loop prefactor in the false vacuum decay rate in a theory of a self interacting scalar field in 3+1 dimensions. We use a numerical method, established some time ago, which is based on a well-known theorem on functional determinants. The proper handling of zero modes and of renormalization is discussed. The numerical results in particular show that quantum corrections become smaller away from the thin-wall case. In the thin-wall limit the numerical results are found to join into those obtained by a gradient expansion.Comment: 31 pages, 7 figure